Chief Executive Officer and Director
Daniel Carcillo is Chief Executive Officer, Director and Co-Founder of Wesana Health. Daniel is a two-time Stanley Cup Champion who played 9 seasons in the National Hockey League. Daniel experienced emotional, sexual and physical trauma within hockey's culture and battled mental health and addiction issues during and post career. When he retired in 2015 at the age of 30, after sustaining his 7th concussion, he founded the Chapter 5 Foundation, a charitable organization that helps athletes transition into life after the game and began to embark on a journey of advocacy work. Daniel’s struggles with Post Concussion Syndrome symptoms led him to seek out psilocybin related treatments, the results of which inspired the formation of Wesana Health and its pursuit of developing and commercializing drug therapies using high dose psilocybin-assisted psychotherapy and psilocybin in a low dose, non-hallucinogenic form to treat, among other ailments, TBI related symptoms.
In addition to the Chapter 5 Foundation, Daniel sits on the Decriminalize Nature National Advisory Board and the board of the Heroic Hearts Project, a registered non-profit that connects military veterans struggling with mental trauma to ayahuasca therapy retreats.
Chief Marketing Officer
Meghna's marketing leadership spans 2 decades with roles in healthcare, retail and the technology sectors. Most recently she led the marketing team for a large multi-clinic dermatology practice and created exceptional patient experiences while exceeding business goals. She is passionate about breaking barriers and removing stigma around mental health. Proud member of Chief (Women's leadership organization), and CAMFT (California Association of Marriage and Family Therapy).
Meghna is commissioner of an all-women's fantasy football league (9 years running), dog mom to Kaashi, and performs traditional Kathak dance. She is a proud alum of Bryn Mawr College, part of the Seven Sisters college consortium.
Chief Financial Officer
Zed Wang is the Chief Financial Officer and Corporate Secretary of Wesana Health. In addition, he is the co-founder and Managing Partner of Jaeger Financial LLP which provides transaction advice, internal financial and controller support and other interim management services to start-up, venture and mid-market companies. Prior to co-founding Jaeger Financial LLP, Zed worked at Auxly Cannabis Group Inc. (TSXV: XLY), as Manager, Decision Support and Accounting Policy, where he provided IFRS guidance to company controllers and external reporting teams, including with respect to biological assets, inventory, and revenue recognition. He also helped develop Auxly’s internal control certification program in compliance with National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual and Interim Filings. Before Auxly, Zed was an Audit Manager at MNP LLP, working with clients in emerging markets, including the cannabis and cryptocurrency sectors. He also participated in the creation of certain of MNP’s national standards with respect biological assets and blockchain accounting.
Zed holds a Master of Accountancy from the Goodman School of Business at Brock University and he is a member of Chartered Professional Accountants of Ontario.
Mark Wingertzahn, PhD
Chief Scientific Officer
Mark Wingertzahn is the Chief Scientific Officer at Wesana Health. Prior to Wesana, Mark held various senior positions at GlaxoSmithKline plc, Pfizer Inc. and Kaleido Bioscience, Inc. overseeing drug research and development, pre-clinical and clinical studies. He has helped achieve FDA and other regulatory approvals for prescription modalities to treat endocrinologic, respiratory, cardiovascular, gastrointestinal pain disorders as well as post-surgical wound healing.
Mark is an instructor of Pediatrics at NYU (Medicine) and Associate Professor of Life Sciences & Allied Health at the NY Institute of Technology College of Osteopathic Medicine. His academic research has focused in the areas of neonatal health, metabolic and rare diseases and has over 50 peer-reviewed publications including in the New England Journal of Medicine.